Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: ACC-001 Clinical Trials Are Ongoing
Publisher:
Journal of Alzheimer's DiseaseDate published:
19 June, 2009Region:
United States of America Publication type:
researchFeatured item on home page:
no
Wyeth Pharmaceuticals, Collegeville, PA, USA
Elan Pharmaceuticals, San Francisco, CA, USA
Pay-Per-View Copyright Statement
Similar entries
- Testing the amyloid hypothesis of Alzheimer's disease in vivo
- Copyright
- PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab...
- The annual Alzheimer Society of Ireland's Tea Day
- Introspective analysis of amyloid as the cause of Alzheimer’s disease: alternative model proposed
- Alzheimer's Disease Neuroimaging Initiative Announces Completion Of Genome-Wide Analysis
- Amyloid-β immunisation for Alzheimer's disease
- 4th annual conference on Clinical Trials in Alzheimer's Disease: Highlights
- Scientists Discover Protein That Fuels Alzheimer's Disease: Medical News Today
- An economic perspective of dementia care in Ireland: Alzheimer's Society of Ireland
